12:00 AM
 | 
Oct 01, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Amitiza lubiprostone regulatory update

Sucampo and Takeda said FDA granted Priority Review to an sNDA for Amitiza lubiprostone to treat opioid-induced constipation in patients with chronic, non-cancer pain. The partners expect an FDA decision by late January 2013, but...

Read the full 155 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >